Market Overview

Mizuho Securities Reiterates Buy on Questcor Pharmaceuticals on Stock Price Weakness

Share:

In a report published Tuesday, Mizuho Securities USA analyst Mario Corso reiterated a Buy rating and $93.00 price target on Questcor Pharmaceuticals (NASDAQ: QCOR).

In the report, Mizuho Securities USA noted, “In the wake of today's stock price weakness on short report that FTC will challenge Synacthen deal, we ascertained that QCOR hasn't received a formal FTC inquiry, and anything informal might just be in response to updated HSR guidelines. Even if FTC pursued a court challenge, could take 2+ years to decide, and most recent product case went in favor of acquirer even though products looked more similar than Acthar/Synacthen.”

Questcor Pharmaceuticals closed on Monday at $56.26.

Latest Ratings for QCOR

DateFirmActionFromTo
May 2014DowngradesBuyNeutral
May 2014DowngradesOverweightNeutral
Apr 2014DowngradesBuyHold

View More Analyst Ratings for QCOR
View the Latest Analyst Ratings

Posted-In: Mario Corso Mizuho Securities USAAnalyst Color Reiteration Analyst Ratings

 

Related Articles (QCOR)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
VIACJP MorganReinstates50.0
NUVASVB LeerinkMaintains92.0
SRPTCantor FitzgeraldMaintains211.0
SRPTPiperJaffrayMaintains210.0
LULUGoldman SachsMaintains219.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

UPDATE: CRT Capital Initiates Coverage on Intuitive Surgical on Structural Shift

UPDATE: Janney Capital Downgrades Francesca's Holdings as Environment Pressures Margins